UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 96

Sortiert nach

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

OncoTargets and therapy, 2018-01, Vol.11, p.4583-4590

2018

Volltextzugriff (PDF)

Immunotherapy for the treatment of Hodgkin lymphoma

Expert review of hematology, 2017-05, Vol.10 (5), p.417-423

2017

Volltextzugriff (PDF)

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

Annals of hematology, 2020-04, Vol.99 (4), p.799-808

2020

Volltextzugriff (PDF)

MCL-113: IBRORS-MCL Study: A Spanish Retrospective and Observational Study of Relapsed/Refractory Mantle-Cell Lymphoma (MCL) Treated with Ibrutinib in Routine Clinical Practice

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S258-S259

2020

Volltextzugriff (PDF)

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7551-7551

2022

Volltextzugriff (PDF)

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain

Blood, 2010-11, Vol.116 (21), p.2793-2793

2010

Volltextzugriff (PDF)

Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

Nuclear medicine communications, 2013-10, Vol.34 (10), p.946-952

2013

Volltextzugriff (PDF)

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood, 2010-11, Vol.116 (21), p.2448-2448

2010

Volltextzugriff (PDF)

Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study

Blood, 2009-11, Vol.114 (22), p.931-931

2009

Volltextzugriff (PDF)

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain

Blood, 2009-11, Vol.114 (22), p.3692-3692

2009

Volltextzugriff (PDF)

rHuEPO in the management of pregnancy complicated by anti-Dib

Transfusion (Philadelphia, Pa.), 2003-05, Vol.43 (5), p.681-682

2003

Volltextzugriff (PDF)

rHuEPO in the management of pregnancy complicated by anti‐Di b

Transfusion (Philadelphia, Pa.), 2003-05, Vol.43 (5), p.681-682

2003

Volltextzugriff (PDF)

rHuEPO in the management of pregnancy complicated by anti-Dib

Transfusion, 2003, Vol.43 (5), p.681-682

2003

Volltextzugriff (PDF)

Enhancing sub-bandgap external quantum efficiency by photomultiplication for narrowband organic near-infrared photodetectors

Nature communications, 2021-07, Vol.12 (1), p.4259-9, Article 4259

2021

Volltextzugriff (PDF)

Whole-Genome Characterization of Rotavirus G9P[6] and G9P[4] Strains That Emerged after Rotavirus Vaccine Introduction in Mozambique

Viruses, 2024-07, Vol.16 (7), p.1140

2024

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(92)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

Immunotherapy for the treatment of Hodgkin lymphoma

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

MCL-113: IBRORS-MCL Study: A Spanish Retrospective and Observational Study of Relapsed/Refractory Mantle-Cell Lymphoma (MCL) Treated with Ibrutinib in Routine Clinical Practice

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain

Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

A Retrospective Population-Based Study of a Series of 307 Treatment-naïve Patients with Chronic Lymphocytic Leukemia (CLL): Study of the Clinical Features and Efficacy of First-Line Therapy

A Retrospective Population-Based Study of a Series of 307 Treatment-naiÃŒË†ve Patients with Chronic Lymphocytic Leukemia (CLL): Study of the Clinical Features and Efficacy of First-Line Therapy

Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain

Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome

R-ESHAP as Salvage Therapy for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Spanish GEL-TAMO Multicenter Study

rHuEPO in the management of pregnancy complicated by anti-Dib

rHuEPO in the management of pregnancy complicated by anti‐Di b

rHuEPO in the management of pregnancy complicated by anti-Dib

Enhancing sub-bandgap external quantum efficiency by photomultiplication for narrowband organic near-infrared photodetectors

Whole-Genome Characterization of Rotavirus G9P[6] and G9P[4] Strains That Emerged after Rotavirus Vaccine Introduction in Mozambique

Suchergebnisse filtern